ReviewCurrent opinion in clinical nutrition and metabolic care2011
Burns: where are we standing with propranolol, oxandrolone, recombinant human growth hormone, and the new incretin analogs?
Review in Current opinion in clinical nutrition and metabolic care, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 66 citations in OpenAlex.
- Endocrine disruptions in thermal injuries: exploring immune system interactions.Physiological reviews · 2026Review
- Metformin is associated with reduced risk of mortality and morbidity in burn patients compared to insulin.Burns : journal of the International Society for Burn Injuries · 2024Article
- Burns: Classification, Pathophysiology, and Treatment: A Review.International journal of molecular sciences · 2023Review
- Drugs Interfering with Insulin Resistance and Their Influence on the Associated Hypermetabolic State in Severe Burns: A Narrative Review.International journal of molecular sciences · 2021Review
- Burn-induced hypermetabolism and skeletal muscle dysfunction.American journal of physiology. Cell physiology · 2021Review
- Glucose Metabolism in Burns-What Happens?International journal of molecular sciences · 2021Review
- Identification of Potential Early Diagnostic Biomarkers of Sepsis.Journal of inflammation research · 2021Article
- Role of anabolic testosterone agents and structured exercise to promote recovery in ICU survivors.Current opinion in critical care · 2020Review
- Anabolic and anticatabolic agents used in burn care: What is known and what is yet to be learned.Burns : journal of the International Society for Burn Injuries · 2020Review
- Nutrition therapy and critical illness: practical guidance for the ICU, post-ICU, and long-term convalescence phases.Critical care (London, England) · 2019Review
- Browning of white adipose tissue after a burn injury promotes hepatic steatosis and dysfunction.Cell death & disease · 2019Article
- Novel pharmacotherapy for burn wounds: what are the advancements.Expert opinion on pharmacotherapy · 2019Review
- Septic predictor index: A novel platform to identify thermally injured patients susceptible to sepsis.Surgery · 2018Article
- The biochemical alterations underlying post-burn hypermetabolism.Biochimica et biophysica acta. Molecular basis of disease · 2017Review
- Specific Etiologies Associated With the Multiple Organ Dysfunction Syndrome in Children: Part 2.Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies · 2017Review
- Diabetes and Sepsis: Risk, Recurrence, and Ruination.Frontiers in endocrinology · 2017Review
- The immune system's role in sepsis progression, resolution, and long-term outcome.Immunological reviews · 2016Review
- A randomized controlled trial to compare the effects of liquid versus powdered recombinant human growth hormone in treating patients with severe burns.Biomedical reports · 2016Article
- Progress in burns research: a review of advances in burn pathophysiology.Annals of burns and fire disasters · 2015Article
- Winning the war against ICU-acquired weakness: new innovations in nutrition and exercise physiology.Critical care (London, England) · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 3 countries.
Funding
Abstract
purpose of reviewThe hypermetabolic response in critically ill patients is characterized by hyperdynamic circulatory, physiologic, catabolic and immune system responses. Failure to satisfy overwhelming energy and protein requirements after, and during critical illness, results in multiorgan dysfunction, increased susceptibility to infection, and death. Attenuation of the hypermetabolic response by various pharmacologic modalities is emerging as an essential component of the management of severe burn patients. This review focuses on the more recent advances in therapeutic strategies to attenuate the hypermetabolic response and its associated insulin resistance postburn. RECENT
findingsAt present, beta-adrenergic blockade with propranolol represents probably the most efficacious anticatabolic therapy in the treatment of burns. Other pharmacological strategies include growth hormone, insulin-like growth factor, oxandrolone and intensive insulin therapy. SUMMARY: Novel approaches to the management of critical illness by judicious glucose control and the use of pharmacologic modulators to the hypercatabolic response to critical illness have emerged. Investigation of alternative strategies, including the use of metformin, glucagon-like-peptide-1 and the PPAR-γ agonists are under current investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.